TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
21 hedge funds and large institutions have $1.66M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 8 closing their positions.
22% less funds holding
Funds holding: 27 → 21 (-6)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
43% less capital invested
Capital invested by funds: $2.9M → $1.66M (-$1.24M)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.25K |
| 3 |
BlackRock
New York
|
+$27 |
| 4 |
JP Morgan Chase
New York
|
+$5 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
-$132K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.1K |
| 3 |
HF
HRT Financial
New York
|
-$14K |
| 4 |
VF
Virtu Financial
New York
|
-$8K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$6.59K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IGWM
26
ICA Group Wealth Management
Denver,
Colorado
| – | -$29 | -5 | Closed |
|
27
Fidelity Investments
Boston,
Massachusetts
| – | -$4 | -1 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5 | -1 | -7% |
|
TCON Hedge Fund Activity: Q3 2023 in Review
21 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2023, worth a combined $1.66M — down 43% from $2.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TCON and 2 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $15.4K. The largest seller was Linden Advisors, exiting entirely with an estimated $132K sold.
- 21 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2023, down from 27 in Q2 2023.
- Funds reported $1.66M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2023, down 43% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 8 closed out, a net change of -6 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $15.4K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was Linden Advisors, an estimated $132K sold.
Based on aggregated 13F filings for Q3 2023.